Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/ki.2013.289

http://scihub22266oqcxt.onion/10.1038/ki.2013.289
suck pdf from google scholar
23903371!ä!23903371
PDF vom PMID23903371 :   free
PDF vom PMID23903371  :  Publisher

suck abstract from ncbi

pmid23903371
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients #MMPMID23903371
  • Martin KJ; Pickthorn K; Huang S; Block GA; Vick A; Mount PF; Power DA; Bell G
  • Kidney Int 2014[Jan]; 85 (1): 191-7 PMID23903371show ga
  • AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, lowers plasma parathyroid hormone in preclinical uremic animal models and in normal healthy individuals. Here, we studied its efficacy in hemodialysis patients suffering from secondary hyperparathyroidism. Major inclusion criteria were hemodialysis for at least 3 months, serum parathyroid hormone over 300 pg/ml, a corrected serum calcium of 9.0 mg/dl or more, and stable doses of vitamin D analogs for at least 3 weeks prior to screening. Twenty-eight patients were enrolled in one of five cohorts (5, 10, 20, 40, 60 mg). Cohorts 1-3 (four patients each) were treated in a two-period crossover design, while cohorts 4 and 5 (eight patients each) were randomized 1:1 to AMG 416 or placebo. Patients were admitted to a clinical research unit following hemodialysis and studied for 3 days prior to discharge for hemodialysis. Single intravenous doses of AMG 416 from 5 to 60 mg were well tolerated, and plasma levels increased in a dose-related manner. AMG 416 treatment was associated with significant, dose-dependent reductions in serum parathyroid hormone and fibroblast growth factor 23. Compared with placebo, all dose groups of 10 mg or more were associated with attenuation in the rise in serum phosphate during the interdialytic period. Dose-dependent reductions in serum calcium were observed and were well tolerated. Thus, AMG 416 represents a novel therapeutic approach for the treatment of secondary hyperparathyroidism in hemodialysis patients.
  • |Adult[MESH]
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Hyperparathyroidism, Secondary/*drug therapy[MESH]
  • |Injections, Intravenous[MESH]
  • |Kidney Failure, Chronic/complications/therapy[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Peptides/administration & dosage/*therapeutic use[MESH]
  • |Renal Dialysis[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    191 1.85 2014